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It is well-known that poor ovarian reserve is a cause of infertility, poor response to
gonadotrophin stimulation and poor success rate after in vitro fertilization (IVF) cycles.
Some years ago a consensus was elaborated on precise criteria which can lead to
a correct identification of poor responders (the Bologna criteria). More recently, the
POSEIDON group has proposed a new stratified classification of patients with low
prognosis, also with the aim of providing clinical indications for the management of these
patients. A literature search was carried out for studies that investigated the ability of
ovarian reserve markers, in particular AMH and AFC, to predict poor ovarian response
in IVF cycles; secondly, studies regarding the Bologna criteria and their prognostic
value were analyzed and available literature on POSEIDON classification was reported.
The most recent markers of ovarian reserve (serum AMH and ultrasound AFC) have
shown to provide a direct and accurate measurement of ovarian follicle pool. These
markers have generally shown comparable predictive power for ovarian response and
a number of retrieved oocytes in IVF cycles. “Abnormal ovarian reserve test” is a very
important parameter both in the Bologna criteria and in the POSEIDON classification.
Several studies have already been published about the reproductive outcome of patients
defined as poor responders according to the ESHRE Bologna criteria: all of them agree
on the poor IVF outcome and low pregnancy rate of these patients. Instead, being
the POSEIDON classification of very recent publication, the efficacy of the POSEIDON
approach in improving management and outcomes of POR patients has yet to be tested
and validated with future prospective clinical trials. Prediction of poor response may help
clinicians choose the stimulation protocol with the aim of gaining patient compliance and
cost reduction, and many efforts have been made by researchers in this sense, including
the formulation of the Bologna criteria and of the POSEIDON classification, in which the
ovarian reserve markers (AMH and AFC) play a fundamental role.
Keywords: IVF, poor response, ovarian reserve markers, AMH, AFC, Bologna criteria, live birth rate, POSEIDON
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INTRODUCTION
In the last decades, a high number of studies has been carried out on the possibility of measuring
ovarian reserve through ovarian reserve markers. In reproductive medicine this is a leading field
of research, as ovarian reserve markers hold an important diagnostic and prognostic value. It is
well-known that a low ovarian reserve may be an important cause of infertility. Moreover, knowing
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the ovarian reserve of a single woman allows clinicians to predict
individual response to controlled ovarian stimulation (COS) in
IVF cycles: if a patient has, for instance, a low ovarian reserve,
she will probably achieve a poor ovarian response after COS. This
condition is characterized by a low number of growing follicles
and low serum estradiol levels after exogenous gonadotropin
stimulation, resulting in a poor oocytes retrieval and, often,
in a poor reproductive outcome (1–5). However, among poor
responder patients the prognosis may be influenced by other
parameters, such as patient’s age and the outcome of previous
IVF cycles.
For this reason, the European Society of Human Reproduction
and Embryology (ESHRE) consensus has recently established
that a response can be defined as poor (POR) when at least two
of the following three criteria are present: (i) advanced female
age (ii) a previous POR (iii) an abnormal ovarian reserve test
(ORT) or in the absence of the above criteria two previous POR
following maximal stimulation (6).
In literature, several studies have already been published on
IVF outcome in poor responder patients defined according to the
Bologna criteria. They all confirm a low live birth rate in these
patients (7–9).
Nevertheless, since a certain heterogeneity concerning some
biological and clinical features among patients included in the
definition of POR still persists, a new classification stratified
in subgroups based on these characteristics as well, that is the
POSEIDON classification, was proposed in order to improve
the performance of tailored therapies in the outcome of these
patients and identify more homogeneous populations to be
included in future clinical trials (10). This review aims at
analyzing the role of ovarian reserve markers (AMH and antral
follicle count) in predicting poor response after COS according
to both classifications. Moreover, we will discuss the ability of
the Bologna criteria to predict a poor reproductive prognosis




Over the years, numerous ovarian reserve markers have been
proposed. Serum FSH, measured in early follicular phase
(day 3–5 of the menstrual cycle) together with estradiol,
has been widely applied in reproductive medicine, but it is
only an indirect marker of ovarian reserve and its blood
concentrations rise only when ovarian reserve is severely
compromised (11). Similarly, literature consistently reports
only a moderate sensitivity and specificity of this marker in
predicting ovarian response to ovarian stimulation. Various cut-
off values ranging from 10 to 15 IU/L have been recommended
for predicting poor response in IVF (12–15), but only few
patients meet this high threshold, limiting the usefulness
of the marker.
The most recent markers of ovarian reserve, i.e., serum
AMH and ultrasound antral follicle count (AFC), have shown
to provide a direct and accurate measurement of ovarian follicle
pool. AMH is produced only by small antral follicles until 6–
8mm diameter and secreted in serum. AFC is performed by
ultrasound and counts all identifiable antral follicles of 2–10mm
present in both ovaries (16–18). As the pool of small antral
follicles measured when performing AFC is the same that secretes
AMH and it is proportional to the overall number of primordial
follicles in the ovaries, AFC and AMH are highly correlated and
show similar values in reflecting oocyte quantity (19).
Comparing AMHwith AFC, AMHhas the advantage of a very
little intra- and inter-cycle variability (20, 21). On top of the well-
known age-related decline in AMH, significant fluctuations have
been reported for a number of conditions and this has to be taken
into account when interpreting values in clinical practice (20).
Fluctuations in the menstrual cycle have also been reported
(22, 23), questioning about using AMH as a single reliable
marker in the clinical situation. But these fluctuations appear
to be random and minor, and limited to high AMH values,
therefore not causing changes in the management of the single
patient. This suggests that in clinical practice AMH can be
measured independently of the cycle phase. The exact role of
patients’ characteristics like ethnicity or lifestyle, for example
habits like smoking, on intra- and inter-individual variability of
AMH needs to be further investigated. Moreover, problems of
low comparability of measured values among laboratories related
to the old manual essays seem nowadays to be solved by the new
recent automated essays, which should guarantee repeatable and
comparable dosages (24). The new automated essays measure
lower AMH concentrations than the old manual essays (−16%
with Access AMH and −20% with Elecsys AMH), but AMH
levels are still strongly correlated to AFC, especially in patients
with low ovarian reserve (24, 25).
On the other hand, AFC exhibits some degree of intra-
and inter-cycle and inter-observer variability (21, 26) that
must be taken into account when considering this marker
for diagnostic purpose. In order to reduce such variability,
recommendations on the methodology and on the equipment
setting have been given (18). The recent introduction of three-
dimensional (3D) automated follicular tracking should decrease
the above mentioned variability (27, 28), but it needs advanced
ultrasound equipment to date, which is not yet largely available.
Direct comparisons between AFC and serum AMH in IVF
cycles have generally shown a similar capacity in predicting
ovarian response and the number of retrieved oocytes. Having
failed in showing an independent relationship between AFC and
oocyte yield, a few studies are in favor of AMH as the strongest
predictor of ovarian response, while other studies have proven
AFC to have a stronger predictive value (29–35). Anyway, these
markers globally predict ovarian response in IVF better than all
other known markers (17, 36–39)
When introducing ovarian reserve markers in clinical
practice with the objective of predicting ovarian response, it is
fundamental to establish acceptable cut-off levels for the markers
themselves. AMH and AFC cut-off values reported in literature
are very variable (4). Such variability could be explained by
factors such as the low number of subjects included in some of
these studies, the variability in the measuring methods used for
the two markers and the different definitions of poor ovarian
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response adopted by the various authors, consequently resulting
in variations in the diagnostic performance of markers of ovarian
reserve. Clinicians should therefore adopt cut-off values from the
published study that may better reflect their clinical setting.
According to published studies, having good sensitivity and
specificity, a cut-off value of AMH ranging between 0.7 and
1.3 ng/ml may be considered acceptable for the prediction of
poor response in IVF (4, 37, 38). Using the most recent
AMH automated essay (Access AMH), the cut-off point at 90%
specificity and 74.1% sensitivity for poor response prediction was
defined 0.93 ng/ml with ROC analysis (25).
AFC can be used to reliably predict ovarian response in IVF
too, but literature shows a considerable variability in agreed
AFC cut-off levels (17, 40). Inevitably, AFC thresholds for
clinical practice depend on available ultrasound technology and
resolution, and therefore need updating over time. Focusing on
the most recent papers, generally based on modern technologies,
the most frequently reported cut-off values for prediction of poor
response range between AFC <5 and <7 (17). AFC thresholds
calculated through modern 3D ultrasound technology haven’t
been published yet.
Thanks to their ability to predict ovarian response to
stimulation, bothmarkers are valid tools for the individualization
of ovarian stimulation treatment and, in particular, for the
choice of the starting dose of FSH (3, 4, 19, 32). A recent
Cochrane review has confirmed that tailoring the FSH starting
dose on ovarian reserve markers may reduce cases of OHSS,
but it has not been able to demonstrate that it improves live
birth rates compared to a policy of giving all women 150 IU
(41). A recent multicenter prospective cohort study with two
embedded RCTs, performed on 1,515 women randomized to an
individualized or standard FSH dose (150 IU), reported the same
conclusions: individualized dosing reduced the incidence of mild
and moderate OHSS, but live births between the two groups were
comparable (42).
Studies on the ability of AMH and AFC to predict oocytes
quality and live births are controversial (32, 43–47). A recent
study by La Marca et al. (48) reported a strong positive age-
independent relationship between circulating AMH and the rate
of euploidy in blastocysts after an IVF cycle (48). According
to this observation, a large cohort study on 1230 IVF-ICSI
cycles reported that AMH and age equivalently predict live
birth (44). On the other hand, a large retrospective study
performed on 69,336 fresh and 15,458 frozen embryo transfer
cycles demonstrated that the areas under the curve (AUC) for
AMH as predictor of live birth in fresh cycles and thawed cycles
were, respectively, 0.631 and 0.540, suggesting that AMH alone is




The occurrence of poor ovarian response in IVF ranges from 10
to 20% and it increases with female age. Once a patient at risk of
poor ovarian response is identified, she should be informed by the
clinician about dramatic prospects. First of all, she will probably
have a poor response to COS, which means a low number of
oocytes retrieved following a standard IVF protocol. This results
in a poor reproductive prognosis, as the chance of an adequate
number of good embryos to transfer is reduced. Moreover, the
clinician should inform the patient that the scientific community
is, so far, not aware of any valid solution, that is of any therapeutic
protocol that could modify or improve the patient’s ovarian
response and prognosis.
This information may be quite stressful for the patient, so
it is necessary to accurately identify poor responder patients
through standardized criteria. However, literature highlights that
this is far from easy: in 2011 a systematic review (49) revealed
that among 47 randomized trials on poor ovarian responders, 41
different definitions for women with poor ovarian response have
been used, with differences both in the criteria considered for the
definition (including age, ovarian reserve markers, outcomes of
a previous IVF cycle like number of follicles on the last day of
ovarian stimulation or number of oocytes retrieved, etc. . . ) and
in the threshold values used for each criteria.
The lack of uniformity in the definition of poor responder
patients has convinced The European Society of Human
Reproduction and Embryology (ESHRE) to elaborate a consensus
where precise criteria lead to the identification of different groups
(or “phenotypes”) of poor responders (6). In order to define
a poor ovarian responder (POR), at least two of the following
three features must be present: (i) Advanced maternal age (≥40
years) or any other risk factor for POR; (ii) A previous POR
(≤3 oocytes with a conventional stimulation protocol);(iii) An
abnormal ovarian reserve test (i.e., AFC<5–7 follicles or AMH<
0.5 −1.1 ng/ml). In the absence of advanced maternal age or
abnormal ORT, two episodes of POR after maximal stimulation
are sufficient to define a patient as a poor responder. In particular,
different categories of POR may be defined from the different
combinations of the Bologna criteria as follows: (i) one previous
poor response and age≥40 years, (ii) one previous poor response
and abnormal markers of ovarian reserve, (iii) age≥40 years and
abnormalmarkers of ovarian reserve (the so-called expected poor
response category), (iv) one previous poor response in a woman
aged≥40 years and with abnormal markers of ovarian reserve, v)
two previous POR cycles following maximal stimulation.
This classification recognizes that the reproductive prognosis
and therefore the definition of POR certainly depends on the
ovarian reserve, measured by AMH or AFC, but also on other
anamnestic and clinical factors, such as age and outcome of
a previous IVF cycle or previous ovarian surgery, which are
integrated into the definition.
Following the consensus, several studies have been published
about the reproductive outcome of patients defined as poor
responders according to the ESHRE Bologna criteria. All of these
studies agree on the poor IVF outcome and low pregnancy rate
of these patients (7–9, 50). In a study by La Marca (7) a database
containing IVF reports from 210 women defined as POR was
analyzed. The study demonstrated that the five different groups
of POR had similar IVF outcomes, with a live birth rate between
5.5 and 7.4%. It was therefore concluded that poor responders
in the five subgroups identified by the Bologna criteria represent
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a homogenous population (7). The same results were reported
in a retrospective study by Busnelli et al. (8), performed on 362
POR undergoing IVF: live birth rate was 6% (95% CI: 4–9%),
not significantly different in the different subgroups of POR (8).
In line with previous studies, in a large retrospective study by
Bozdag et al. (9) performed on 821 patients fulfilling the Bologna
criteria, the live birth rates per started IVF cycle ranged from
2.3 to 8.7%. In contrast with previous studies, the subgroup of
POR presenting AFC<7 and a previous poor ovarian response,
defined as “young proven” PORs subgroup, was found to be
associated with the most favorable live birth and implantation
rates, compared to other subgroups, characterized by patients’
age >40 and a previous poor response and/or AFC < 7 (9).
By better identifying the perimeter of patients to be considered
as poor responders, the Bologna Criteria certainly represent an
important step in the definition of POR and for the prediction
of an IVF cycle, thus allowing clinicians to provide patients with
improved counseling.
A few authors (10, 51–53) have, however, focused on clinical
and biological aspects that would deserve greater consideration
in the classification of poor patients (including the age-related
oocyte quality and the genetic profile that conditions the ovarian
sensitivity to the stimulation with the gonadotropins). These
authors have highlighted how, with regard to these aspects,
there is a persistent heterogeneity among POR patients and have
criticized the lack of indication of differentiated management
strategies for the different subgroups of patients (Table 1). This
means that the same type of treatment may not be optimal for
all the patients defined as POR, even when having a similar
prognosis. While this may have a logical basis, it is far from
being proved on a solid scientific ground made of well-designed
multicenter trials. Up to now, there is not sufficient evidence
for clinicians to recommend a particular therapeutic strategy
resulting in improved live birth rate for poor responder women.
Treatment with a GnRH antagonist protocol instead of a
GnRH agonist protocol was proposed for these patients as
it avoids the very deep suppression of endogenous FSH and
LH concentrations in the early follicular phase at the stage of
follicular recruitment, thus giving hope for a better egg retrieval.
Some trials and meta-analyses actually showed that the GnRH
agonist long protocol and the GnRH antagonist regimen are
comparable in their efficacy for the outcome of IVF in poor
responders (55–57).
In this regard, we think that if the standard agonist long
protocol offers no benefits in poor reponder patients in terms of
chance of pregnancy when compared to an antagonist protocol,
the choice of the protocol should aim to improve patient
compliance (58) in addition to cost reduction (59). This is
possible with an antagonist protocol as it allows shorter duration
of stimulation and reduced gonadotrophin consumption (4, 60).
In this context, a recent large randomized trial demonstrated
the non-inferiority of a mild ovarian stimulation protocol
with GnRH antagonist compared to a standard approach with
the long GnRH agonist protocol. Ongoing pregnancy rate
was 12.8% (25/195) for mild ovarian stimulation vs. 13.6%
(27/199) for conventional ovarian stimulation (95% CI: 0.57–
1.57), while the duration of ovarian stimulation and the amount
of gonadotrophins used were significantly lower in the mild
stimulation strategy (61).
Different studies performed on women predicted to be poor
responders showed that increasing the FSH dose doesn’t impact
on the number of retrieved oocytes (62, 63). The maximum
TABLE 1 | Summary of the existing literature on Poseidon classification.
Author Publication Type of article Main finding
Poseidon Group (Patient-Oriented
Strategies Encompassing IndividualizeD
Oocyte Number), Alviggi et al. (10)
Fertil Steril. 2016; 105(6):1452–3 Commentary Definition of Poseidon categories:
Group 1: Patients < 35 years with sufficient prestimulation
ovarian reserve parameters (AFC ≥5, AMH ≥1.2 ng/mL) and
with an unexpected poor or suboptimal ovarian response.
Group 2: Patients ≥ 35 years with sufficient prestimulation
ovarian reserve parameters (AFC ≥5, AMH ≥1.2 ng/mL) and
with an unexpected poor or suboptimal ovarian response.
Group 3: Patients < 35 years with poor ovarian reserve
prestimulation parameters (AFC <5, AMH <1.2 ng/mL).
Group 4: Patients ≥ 35 years with poor ovarian reserve
prestimulation parameters (AFC <5, AMH <1.2 ng/mL).
Humaidan et al. (54) F1000Res. 2016; 5:2911 Commentary Definition of Poseidon categories and discussion as to why
the new concept has been proposed
Haahr et al. (52) Reprod Biol Endocrinol. 2018;
16(1):20.
Review Discussion on how the treatment of the expected poor
ovarian response patient should be individualized in all steps
of ART, including the choice of GnRH analog, the
gonadotropin type and dose, ovulation trigger, and the
possible use of adjuvant therapies.
Esteves et al. (53) Front Endocrinol (Lausanne).
2018; 9:461.
Review Critical appraisal of the existing criteria that standardize the
definition of POR and explanation of reasons for the
development of the POSEIDON criteria.
Frontiers in Endocrinology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 281
Grisendi et al. Poor Ovarian Response Prediction and Management
number of oocytes that can be retrieved in women is determined
by the number of recruitable antral follicles in the ovaries and it
is obvious that a dose of FSH higher than the maximal one will
never compensate for the lack of substrate.
Recently, new ovarian stimulation protocols are under study
for their application on poor responders. Among these, the
double ovarian stimulation, that is the ovarian stimulation in
follicular and luteal phases within a single ovarian cycle, seems
capable of increasing the number of retrieved oocytes and
available embryos for the single patient (64). The first data have
been published on possible advantages of a GH co-treatment
with the mild stimulation protocol or the GnRH antagonist
protocol in poor responders (65–67). Some RCTs and meta-
analysis have also been published regarding LH supplementation
within the rFSH stimulation in IVF cycles: there is no agreement
on the benefit of this therapy in the general population, while
particularly in POR patients it showed an improvement of
the clinical pregnancy rate and live birth rate (51, 52, 68,
69). Supplementation with androgens also seems to give some
positive results in these patients, although the available trials
are still too low in number to make recommending such a
therapy possible (52). Finally, a few studies report that a dual
trigger ovulation regimen with GnRH agonist plus hCG could
significantly improve number and maturity of retrieved oocytes
in poor responders, but more studies are needed to evaluate
a possible positive effect of the dual trigger on the clinical
pregnancy rate (70, 71).
In this context, in order to differentiate more homogeneous
subgroups of patients that could benefit from a specific
management, in 2016 Alviggi and the POSEIDON group
attempted to develop a new classification in which patients
defined as “low prognosis” were divided in four groups according
to age, ovarian reserve and ovarian response (Table 2). In the
POSEIDON classification a poor ovarian reserve pre-stimulation
is defined on the basis of ovarian reserve markers, precisely AFC
<5 or AMH <1.2 ng/ml. This identifies the so-called “expected
poor ovarian responders”: these patients belong to GROUP 3
if they are aged < 35 years or GROUP 4 if they are > 35
years old; the 2 groups with the same low ovarian reserve are
thus differentiated for the oocyte quality and therefore for the
expected aneuploidy rate of the oocytes taken. As a matter
of fact, there is in literature a quite broad agreement that 35
years of age represent the beginning of age-related changes not
only in oocytes quantity, but also in their quality (with an
embryo euploidy rate that decreases by 2.4 percentage points
for every year increase in female age and a blastocyst euploidy
rate that drops from 60% before 35 years to 30% after 40 years,
and a subsequent decline in implantation potential) (54, 72).
In a subsequent review (52) the suggested recommendations
for these categories of patients have been better explained: the
number of oocytes necessary to obtain at least one euploid
embryo for transfer in each patient is estimated between 4 and
7 for group 3 and 12 oocytes for group 4; suggested treatments
in both groups include both the long GnRh agonist protocol
and the GnRh antagonist protocol, ovarian stimulation with
300 IU/day of rFSH, with rLH adjuvant therapy for group
4, the possibility of performing a double stimulation with an
TABLE 2 | Comparison between Bologna criteria and Poseidon’s stratification.
Bologna criteria Poseidon’s stratification
1) Maternal age ≥40 years + A
previous POR
GROUP 1
Age <35 years +
adequate ORT +
An unexpected POR (<9 oocytes retrieved)
2) An abnormal ORT (AFC <5–7
follicles or AMH< 0.5
−1.1 ng/ml) + A previous POR
GROUP 2
Age ≥35 years +
adequate ORT +
An unexpected POR (<9 oocytes retrieved)
3) Maternal age ≥40 years + An
abnormal ORT (AFC <5–7
follicles or AMH< 0.5
−1.1 ng/ml)
GROUP 3
Age <35 years +
An abnormal ORT (AFC<5;
AMH<1.2 ng/ml)
4) Maternal age ≥40 years + An
abnormal ORT (AFC <5–7
follicles or AMH< 0.5
−1.1 ng/ml) + A previous POR
GROUP 4
Age ≥35 years +
An abnormal ORT (AFC<5;
AMH<1.2 ng/ml)
5) 2 previous POR
oocyte/embryo accumulation and frozen embryo transfer. The
use of an androgen adjuvant therapy (DHEA, testosterone) needs
further investigation before it can be recommended whereas the
possibility of oocyte donation is only considered in group 4.
GROUPS 1 and 2 of the POSEIDON classification include
instead the “unexpected poor ovarian response,”i.e., those
patients who, despite having a good ovarian reserve based on
the values of the ovarian reserve markers (AFC> 5, AMH>
1.2mg / ml), obtained a low oocyte number: between 4 and 9
oocytes retrieved (subgroups 1-a and 2-a) or even fewer than
4 oocytes retrieved (subgroups 1-b and 2-b). Once again, given
the same ovarian response, the two groups are distinguished
according to the age of the patients (group 1 <35 years, group
2> 35 years). A poor response in these patients may be due
to iatrogenic hypostimulation or also to genetic polymorphism
in FSH receptors (FSHR), LH receptor (LHR) or LH. It is
actually reported in the literature that some polymorphisms
in the alleles coding for these molecules (such as the FSHR
Ser680 allele, or the LHβ variant) are associated with higher
FSH consumption, thus characterizing patients requiring higher
doses of rFSH during the controlled ovarian stimulation for ART
(52, 73, 74). At the current state of knowledge, no hormonal or
ultrasound marker exists that allows for the early recognition
of these polymorphisms in the single patient. Furthermore, an
adjuvant therapy with rLH supplementation is suggested in this
subgroup to increase the implantation rate and in group 2 to
improve the oocyte quality also (68). Finally, it seems that genetic
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polymorphisms in FSH receptor are not associated to significant
variation in ovarian reserve markers (75, 76).
Obviously the efficacy of the POSEIDON approach in
improving management and outcomes of POR patients will have
to be tested and validated with future prospective clinical trials.
Moreover, AMH and AFC cut-off values for poor and normal
response prediction will probably be updated in the next years,
together with the spread of new AMH automated essays end
modern ultrasound technology. As a consequence, POSEIDON
categories might undergo a revision in the inclusion criteria on
the ground of ovarian reserve markers.
CONCLUSIONS
Serum AMH and ultrasound AFC have shown to provide a
direct and accurate measurement of ovarian follicle pool. These
markers have generally shown a similar capacity to predict
ovarian response and number of retrieved oocytes in IVF cycles.
In spite of this, the definition of a patient as poor responder
appears heterogeneous in literature, also for the fact that not only
the ovarian reserve, but also other clinical-anamnestic factors
are important in determining a poor response to COS. This
is not irrelevant if we consider the clinical and psychological
implications of a POR diagnosis. The development of the Bologna
Criteria and of the POSEIDON classification, combining the
ovarian reserve markers with age, with the previous response
to COS and with other risk factors for POR, aims at providing
a significant help in the standardization of the criteria used for
this diagnosis and in the improvement of these patients’ clinical
management. While waiting for studies conducted on the new
criteria, we can say that, according to the data currently available
in literature, the prediction of poor response and the use of
consequently tailored treatment can have positive results in terms
of patient compliance and cost reduction, but it does not seem to
involve a relevant improvement in IVF outcome (60, 77).
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